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Genetics of ulcerative colitis: the
come-back of interleukin 10
Edouard Louis,1,2 Cecile Libioulle,2 Catherine Reenaers,1,2
Jacques Belaiche,1 Michel Georges2
Crohn’s disease and ulcerative colitis are
chronic, immune-mediated inflammatory
diseases of the gastrointestinal tract,
affecting up to 0.4% of the population in
Western countries.1 They are considered
complex multifactorial polygenic diseases.
While dramatic progress has been made in
deciphering the genetic architecture of
Crohn’s disease, ulcerative colitis was
somewhat left behind, with virtually no
relevant studies published until very
recently. Although both disorders are
considered to belong to the same spec-
trum of pathologies, the first gene clearly
associated with Crohn’s disease (CARD-
15)2 3 did not seem to predispose to
ulcerative colitis in any cohort in which
it was tested. This finding highlighted
some pathogenic differences between the
two diseases, and reminded geneticists
working on inflammatory bowel diseases
(IBDs) of the more modest contribution
of genetics to the predisposition to ulcera-
tive colitis, reflected in a lower ratio of
disease concordance between monozygo-
tic and dizygotic twins.4 The lower herit-
ability of ulcerative colitis also accounts
for the fact that most of the linkage
studies performed in the 1990s did not
include sufficient ulcerative colitis-
affected sib pairs to disclose ulcerative
colitis-related loci. With few exceptions,5–7
reports of associations with candidate
genes have not been confirmed.
Recently, major advances in cataloguing
common genetic variants in humans
combined with the development of high-
throughput single nucleotide polymorph-
ism (SNP) genotyping capacity, have
made large-scale, genome-wide associa-
tion studies (GWASs) with hundreds of
thousands of common SNPs feasible.
These have dramatically increased the list
of loci shown to be associated with
Crohn’s disease,8–13 and now also with
ulcerative colitis14–17 (table 1).
First, a series of loci previously shown
to be associated with Crohn’s disease
were tested for their effect on the predis-
position to ulcerative colitis in cohorts of
appropriate size. A substantial number
were found to be associated with ulcera-
tive colitis, including important immuno-
logical players such as IL23R or IL12B.14 In
some cases, notably HERC2 and STAT3,
the associations seemed even stronger for
ulcerative colitis than for Crohn’s disease.
A genome scan with non-synonymous
SNPs subsequently revealed novel associa-
tions specific for ulcerative colitis.15
Among these, the strongest association
was for two SNPs at the ECM1 locus.
Although fine mapping is needed to
clearly identify the causative variants,
ECM1 itself is a relevant candidate gene
for ulcerative colitis, as it is implicated in
the interaction between epithelium and
basal membrane and strongly activates
nuclear factor kB (NF-kB) signalling.18 The
same SNPs were previously shown to be
weakly associated with ankylosing spon-
dylitis, thus slowly adding to the fascinat-
ing genetic jigsaw of immune-mediated
inflammatory disease.19 Other strong
associations were found for variants
within the HLA complex, including
HLADQA1, HLADRA, HLADRB5 and
HLADRB1. These confirmed previously
reported associations, particularly for
HLADRB1.20 Very interestingly, HLA var-
iants predisposing to ulcerative colitis
were shown to increase risk for pure
colonic Crohn’s disease while protecting
against pure ileal Crohn’s disease, thus re-
emphasising major genetic differences
between ileal and colonic IBDs, as pre-
viously noted for CARD15.
Finally, two full GWASs for ulcerative
colitis were published very recently.16 17 In
the first European study, 440 794 SNPs
were first genotyped in 1167 Caucasian
patients with ulcerative colitis and 777
healthy controls.16 Twenty of the most
significant associations were tested for
replication in three independent European
case–control panels comprising a total of
1855 patients with ulcerative colitis and
3091 controls. In addition to disclosing
new SNPs associated with ulcerative
colitis in the HLAII-BTNL2 region, this
study revealed two important brand new
associations The first is with SNPs near
the ARPC2 locus. The function of ARPC2
in human is not known. The microbial
equivalent of ARP2/3 associates with the
protein encoded by the WAS gene
(involved in the Wiskot–Aldrich syn-
drome) which plays a role in the regula-
tion of regulatory T cells.21 The second
new association is with SNPs near the 39-
UTR of the IL10 gene at 1q32. The latter
SNPs were the most significantly asso-
ciated (outside the HLA complex), with p
values reaching 1.35610212 in the com-
bined analysis and an odds ratio of 1.46
(1.31–1.62). The second study from the
United States included, overall for the
GWAS and two replication cohorts, 2439
patients with ulcerative colitis and 3686
controls all of European ancestry.17 This
study confirmed association with several
SNPs at the IL23R locus on chromosome
1p31 and with a region spanning BTNL2
to HLA-DQB1 on chromosome 6p21. It
also showed new association with loci on
chromosomes 1p36 and 12q15. Important
candidate genes at these loci are PLA2GE2,
coding for a secretory phospholipase A2,
as well as IFNG (interferon gamma, a
critical cytokine in the immune response
to pathogens) IL22 and IL26 (interleukin
22 and interleukin 26 secreted by TH-17
cells).
The strong association with the IL10
gene found in the European GWAS is
arguably one of the most exciting. A fine
mapping strategy confirmed the associa-
tion with the IL10 locus and suggested the
possibility of multiple causative variants
which, however, remain to be clearly
identified.
It has been recognised for a long time
that IL10 is a very important anti-inflam-
matory cytokine in intestinal immune
homeostasis, potentially involved in the
pathogenesis of IBD. The first convincing
evidence for an implication of IL10 in
intestinal immune regulation and in the
development of enterocolitis came from
IL102/2 mice which spontaneously
develop enterocolitis.22 In this model, the
inflammation mainly affects the mucosa
along the gastrointestinal tract and is
characterised in the colon by enlarged
and branched crypts, reduced number of
goblet cells, degeneration of superficial
epithelial cells and increased expression of
major histocompatibility complex (MHC)
class II molecules. An important protec-
tive role of IL10 was also obtained in
alternative models of colitis, including the
transfer of CD4+ CD45RBhigh T cells to
1 Department of Gastroenterology, CHU of Lie`ge,
University of Lie`ge, Belgium; 2 GIGA Research, University
of Lie`ge, Belgium
Correspondence to: Dr Edouard Louis, Department of
Gastroenterology, CHU of Lie`ge, 4000 Lie`ge, Belgium;
Edouard.louis@ulg.ac.be
Leading article
Gut September 2009 Vol 58 No 9 1173
 on 10 November 2009 gut.bmj.comDownloaded from 
immunodeficient mice. In this system,
colitis can be prevented or cured by the
co-transfer of IL10 producing regulatory T
cells.23 Production of IL10 by these cells
was shown to be essential for the preven-
tion or cure of colitis. During the healing
process, IL10-producing regulatory T cells
selectively accumulate within the colonic
lamina propria, suggesting compartmenta-
lisation of these regulatory T cells at
effector sites. These IL10 defect dependent
colitis models do not develop in germ-free
mice, highlighting the role of intestinal
bacteria in the stimulation of chronic
inflammation.24 Appropriate production of
IL10 could thus regulate the mucosal
immune response to the enteric flora,
preventing the development of chronic
inflammation. Bacteria-induced chronic
inflammation of the colon has also been
associated with the development of colonic
cancer, mimicking what may happen in
ulcerative colitis. Here again, IL10 appeared
to play a key role in preventing tumour
development.25 Besides germs, drugs (such
as non-steroidal anti-inflammatory drugs
(NSAIDs)) and stress may favour the
development of colitis in predisposed sub-
jects. Indeed, in IL10-deficient mice,
NSAIDs induced rapid development of
colitis with infiltration of macrophages
and interferon-gamma-producing CD4+ T
cells in the lamina propria,26 which per-
sisted after withdrawal of the NSAID. In
wild-type mice, NSAIDs had minimal
effect on the colon. Also, in vitro produc-
tion of IL10 by peripheral blood cells under
b-adrenergic stimulation was decreased in
ulcerative colitis patients, suggesting a
protective role of IL10 against stress-related
colitis.27 IL10 thus appears to play a key role
in many aspects of the regulation of the
immune-mediated inflammatory reaction
characterising IBDs (fig 1). The mechanism
by which IL10 can attenuate or prevent
Table 1 Single nucleotide polymorphisms (SNPs) significantly associated with ulcerative colitis, identified through genome-wide association
studies15–17 or systematic testing after significant association with Crohn’s disease in genome-wide association studies14
Chromosome Gene Disease SNP Amino acid shift Study
1p31 IL23R Ulcerative colitis rs1004819 Silverberg et al17
1p31 IL23R Ulcerative colitis rs10889677 Silverberg et al17
1p31 IL23R Crohn’s disease,
ulcerative colitis
rs11209026 R381Q Fisher et al,15 Silverberg et al17
1p31 IL23R Ulcerative colitis rs11465804 Silverberg et al17
1p31 IL23R Crohn’s disease,
ulcerative colitis
rs11805303 Fisher et al,15 Franke et al16
1p36 Intergenic (OTUD3, PLA2G2E) Ulcerative colitis rs3806308 Silverberg et al17
1p36 Intergenic (OTUD3, PLA2G2E) Ulcerative colitis rs10753575 Silverberg et al17
1p36 Intergenic (OTUD3, PLA2G2E) Ulcerative colitis rs6426833 Silverberg et al17
1q21.2 ECM1 Ulcerative colitis rs3737240 T130M Fisher et al15
1q21.2 ECM1 Ulcerative colitis rs13294 G290S Fisher et al15
1q32 IL10 Ulcerative colitis rs3024505 Franke et al16
1q32 KIF21B-CACNA1S Crohn’s disease,
ulcerative colitis
rs17419032 Franke et al14
2q35 ARP2C Ulcerative colitis rs12612347 Franke et al16
3p21 MST1 Crohn’s disease,
ulcerative colitis
rs3197999 R689C Fisher et al15
3p21 BSN Crohn’s disease,
ulcerative colitis
rs9858542 Franke et al,14 Fisher et al15
5q33 IL12B Crohn’s disease,
ulcerative colitis
rs6556416 Fisher et al15
5q33 IL12B Crohn’s disease,
ulcerative colitis
rs6887695 Franke et al14
6p21 HLA Crohn’s disease,
ulcerative colitis
rs660895 Fisher et al15
6p21 HLA Ulcerative colitis rs9268877 Franke et al16
6p21 HLA Ulcerative colitis rs9268858 Franke et al16
6p21 HLA/BTNL2 Crohn’s disease,
ulcerative colitis
rs9268480 Fisher et al,15 Franke et al16
6p21 HLA/BTNL2 Ulcerative colitis rs2395185 Silverberg et al17
10p11 CCNY Crohn’s disease,
ulcerative colitis
rs3936503 Franke et al14
10q21 intergenic Crohn’s disease,
ulcerative colitis
rs10761659 Franke et al,14 Fisher et al15
10q24 NKX2–3 Crohn’s disease,
ulcerative colitis
rs10883365 Franke et al,14 Fisher et al15
10q24 NKX2–3 Crohn’s disease,
ulcerative colitis
rs11190140 Franke et al14
12q15 Intergenic (IFNG, IL22, IL26) Ulcerative colitis rs7134599 Silverberg et al17
12q15 Intergenic (IFNG, IL22, IL26) Ulcerative colitis rs1558744 Silverberg et al17
12q15 IL26 Ulcerative colitis rs2870946 Silverberg et al17
15q13 HERC2 Crohn’s disease,
ulcerative colitis
rs916977 Franke et al14
17q21 STAT3 Crohn’s disease,
ulcerative colitis
rs744166 Franke et al14
18p11 PTPN2 Crohn’s disease,
ulcerative colitis
rs2542151 Franke et al14
For SNPs in intergenic regions, candidate genes in the vicinity are given in brackets.
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colitis involves inhibition of pro-inflamma-
tory cytokines and prevention of endoplas-
mic reticulum stress. In particular, IL102/
2 mice lack transforming growth factor b/
Smad signalling and fail to inhibit proin-
flammatory gene expression in intestinal
epithelial cells after the colonisation with
colitogenic bacteria.28 Also, proteomic ana-
lysis of functional epithelial cells showed
that IL10 can block endoplasmic reticulum
stress and chronic inflammation by mod-
ulating activating transcription factor
(ATF)-6 nuclear recruitment to the grp-78
gene promoter.29
The exact nature of the IL10 defect in
ulcerative colitis remains to be discovered.
Previous studies have not shown a dra-
matic decrease in IL10 production in the
colonic mucosa of ulcerative colitis
patients. In contrast, in inflamed mucosa,
a very significant increase of IL10 levels
was observed.30 31 Nevertheless, reduced in
vitro regulation of IL10 has been shown in
inflammatory immune cells of ulcerative
colitis patients.32 The defect in ulcerative
colitis could involve the diminished pro-
duction by specific cell populations, such as
epithelial or regulatory T cells, an abnormal
response to specific stimuli, or the produc-
tion of an IL10 with diminished affinity for
its receptors. One of the main SNPs
associated with ulcerative colitis is located
very closely to a highly conserved stretch of
DNA containing a putative activating
protein-1 (AP-1) binding site.16 AP-1 can
be activated by lipopolysaccharide in
macrophages. IL10 could thus be part of a
regulatory response to such stimulation.
Two new exonic SNPs were also found by
re-sequencing the IL10 gene.16 These var-
iants could influence the binding of IL10 to
its high-affinity receptor A.
Despite encouraging initial results in
treating mild-to-moderate ulcerative coli-
tis with human recombinant IL10,33
enthusiasm for the effectiveness of IL10
in the prevention and treatment of colitis
has been tempered by its failure to induce
remission or prevent recurrence in
Crohn’s disease controlled trials.34 35
Interestingly, the SNPs associated with
ulcerative colitis in the recent study by
Franke et al were only weakly associated
with Crohn’s disease, suggesting a more
prominent pathogenic role for IL10 in
ulcerative colitis than in Crohn’s disease.16
Whatever the nature of the IL10 defect in
ulcerative colitis, the development of
IL10-based treatment of ulcerative colitis
should now be a priority. Unravelling the
precise nature of the underlying defect
may guide the choice between alternative
treatment options, including systemic
injection, topical administration,
enhancement of production by probio-
tics36 or even local production of IL10 by
genetically modified probiotics.37 A sys-
temic administration, as tested mainly in
Crohn’s disease, would probably be sub-
optimal to correct a selective defect of
production in epithelial cells or mucosal
regulatory T cells upon stimulation by
luminal bacterial components.
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Robin Spiller, editor
Epigastric pain and elevated
pancreatic enzymes
CLINICAL PRESENTATION
A 54-year-old man presented with epigastric abdominal pain
radiating to the back of several days duration. The pain was
continuous and not associated with nausea, vomiting or food
intake. On examination he was noted to have slight tenderness
over the epigastric region and no organomegaly. Laboratory
investigations including liver function tests, complete blood
count and urinalysis were normal except for an elevation in the
serum amylase (165 IU/l) and lipase (241 IU/l) levels.
Abdominal ultrasound was negative for any biliary pathology
and the pancreatic parenchyma displayed normal echogenicity.
The patient was treated conservatively but failed to improve. A
64-slice CT scan was obtained (fig 1). Upper endoscopy
revealed a submucosal bulge 1–2 cm below the gastro-
oesophageal junction along the lesser curvature with an intact
overlying gastric mucosa. Endoscopic ultrasound further
revealed that the mass was arising from the muscularis propria
layer of the gastric wall with mixed echogenicity and central
hypodensity.
QUESTION
What is your diagnosis?
See page 1199 for the answer.
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Figure 1 CT scan of the abdomen showing a 4.262.3 cm enhancing
soft tissue mass (white arrow) along the lesser curvature of the stomach
with a hypodense central area consistent with central necrosis.
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